Drug Resistance and Persistence in Tuberculosis
Organizer(s): Ann M. Ginsberg and John D. McKinneyDate: May 13 - 18, 2012
Location: Speke Resort & Conference Centre, Kampala, Uganda
According to the World Health Organization, over 25% of new tuberculosis cases in some subnational regions are multi-drug-resistant TB (MDR-TB) and, as of March 2010, 58 countries had reported XDR-TB (TB resistant to the major classes of both first- and second-line drugs). The Keystone Symposia meeting on Drug Resistance and Persistence in Tuberculosis aims to bring together basic and clinical researchers and public health experts from diverse backgrounds to explore the following: 1) the fundamental biology underlying genetic and phenotypic drug-resistance in TB; 2) progress in expanding capacity in high-burden settings to perform drug susceptibility testing; 3) identification of novel drug targets; 4) innovative strategies for drug discovery; and 5) advances in developing multi-drug regimens that will be effective against currently drug-resistant as well as drug-sensitive strains of M. tuberculosis. Investigators from outside the TB field will be included to provide new perspectives and stimulate fresh approaches for tackling this global public health priority.
Global Health Travel Award Deadline: December 13 2011
Scholarship Deadline: January 13 2012
Discounted Abstract Deadline: January 13 2012
Abstract Deadline: February 14 2012
Discounted Registration Deadline: March 16 2012
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
GlaxoSmithKline / DDDW
$2,500 - $9,999
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI098285-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.